Who can participate in this Non-Small Cell Lung Cancer study?

Eligibility varies by study, but generally includes adults diagnosed with Non-Small Cell Lung Cancer who meet specific medical criteria. Complete the interest form above to learn if you may qualify.

Is the study available in Anchorage, Alaska?

Yes! This study has active research sites in Anchorage, Jonesboro, Anaheim. When you express interest, you'll be connected with the site nearest to you.

What are the benefits of joining a clinical trial for Non-Small Cell Lung Cancer?

Participants often receive: access to new treatments before they're widely available, close monitoring by medical professionals, study-related care at no cost, and the opportunity to contribute to medical research.

⚡Your ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT06616584RECRUITINGIRB Ready

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Sponsored by SWOG Cancer Research Network

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

📊

1 of 378 participants interested

0% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

First Name *

Last Name *

Email Address *

Phone Number *

ZIP Code *

Age Range *

Preferred Location

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

No-Cost Study Care
Advance Medical Science
Contribute to groundbreaking research
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel (varies by study)
Help Others
Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

1Submit this form
2Phone screening
3In-person assessment if eligible
4Begin participation

About This Study

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system.

Who Can Participate

Inclusion Criteria

Participants must have been assigned to S1800E by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1800E is determined by the LUNGMAP protocol

Participants must have measurable or non-measurable disease documented by CT or MRI. The CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality. Measurable disease must be assessed within 28 days prior to randomization. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to randomization. All disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration

❓ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

📋

Study Type

INTERVENTIONAL

👥

Target Enrollment

378 participants

⚧

Gender

ALL

🏢

Sponsor

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

🔒 Secure · 🏥 Expert Care

Looking for Non-Small Cell Lung Cancer Treatment in Anchorage?

Join others in Alaska exploring innovative treatment options through clinical research

Non-Small Cell Lung Cancer Treatment Options in Anchorage, Alaska

If you're searching for Non-Small Cell Lung Cancer treatment in Anchorage, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Anchorage, Jonesboro, Anaheim and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Non-Small Cell Lung Cancer. All study-related care is provided at no cost to participants.

Local Sites

3 locations in Alaska

Now Enrolling

Up to 378 participants

Quick Start

Screening available now

Why Consider a Clinical Trial for Non-Small Cell Lung Cancer?

Potential Benefits

✓Access to new treatment approaches before public availability
✓Close monitoring by experienced medical professionals
✓Study-related care provided at no cost
✓Contribute to medical research for Non-Small Cell Lung Cancer

What to Expect

→Initial screening to determine eligibility
→Regular check-ups and monitoring visits
→Possible compensation for time and travel
→You can withdraw at any time

Frequently Asked Questions About This Non-Small Cell Lung Cancer Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06616584. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.